Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

  1. Griesinger, F.
  2. Curigliano, G.
  3. Thomas, M.
  4. Subbiah, V.
  5. Baik, C.S.
  6. Tan, D.S.W.
  7. Lee, D.H.
  8. Misch, D.
  9. Garralda, E.
  10. Kim, D.-W.
  11. van der Wekken, A.J.
  12. Gainor, J.F.
  13. Paz-Ares, L.
  14. Liu, S.V.
  15. Kalemkerian, G.P.
  16. Houvras, Y.
  17. Bowles, D.W.
  18. Mansfield, A.S.
  19. Lin, J.J.
  20. Smoljanovic, V.
  21. Rahman, A.
  22. Kong, S.
  23. Zalutskaya, A.
  24. Louie-Gao, M.
  25. Boral, A.L.
  26. Mazières, J.
  27. Erakutsi egile guztiak +
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2022

Alea: 33

Zenbakia: 11

Orrialdeak: 1168-1178

Mota: Artikulua

DOI: 10.1016/J.ANNONC.2022.08.002 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus